Beyond Clinical Success: Bianca Gustafson on Building Supply Chains That Scale 

In a recent Contract Pharma interview, Bianca Gustafson, Senior Director of Program Management at Cryoport Systems, shared an important perspective on the transition from clinical development to commercialization. According to Gustafson, a common mistake organizations make is assuming that commercial readiness is an extension of clinical operations, when actually commercialization requires a full-on shift in how supply chains are designed and scaled. 

While clinical programs often succeed through highly coordinated, hands-on management, commercial operations require a different level of operational discipline. As therapies advance toward approval and market launch, organizations must begin thinking beyond individual shipments and immediate milestones to build systems that support long-term growth. 

From Coordination to Orchestration 

One of the key themes Gustafson highlighted is the shift from coordination to orchestration. 

Early-phase clinical supply chains often rely on a reactive approach, with teams intervening to resolve issues in real-time. While this approach can be effective at small scale, as programs expand into additional geographies, complexity grows rapidly. What once worked through individual effort and informal processes becomes increasingly difficult to sustain with higher shipment volumes and a multiple-vendor partner engagement model. 

Commercial success requires organizations to establish defined governance and clear escalation pathways to support consistent execution. Reactive problem-solving isn’t sustainable and sponsors must create an environment where processes are repeatable and scalable. 

According to Gustafson, this evolution is one of the most significant operational shifts companies will face on the path to commercialization. 

Growing Pains 

Commercialization introduces a web of interconnected variables that can significantly elevate risk. 

Every new manufacturing site, distribution partner, country launch, and regulatory requirement adds another layer of complexity. As these interdependencies multiply, organizations can quickly find themselves managing a network that is far more challenging than delivery to the clinic. 

Gustafson emphasizes that the risks associated with commercialization are often underestimated because they do not emerge from a single point of failure. Instead, challenges frequently arise at the intersection of functions, partners, and processes. Without program-level oversight and visibility, even small disconnects can create downstream disruptions.  Scalability should not be viewed solely through the lens of capacity. True scalability also requires operational alignment and control. 

Why Commercial Readiness Starts Early 

A recurring message that Gustafson highlights is commercial readiness begins long before a product approaches launch. 

Many of the decisions made during clinical development will ultimately influence commercial success. Supply chain design, logistics strategy, partner selection, technology infrastructure, and governance frameworks all contribute to how effectively an organization can scale in the future. 

Organizations that postpone commercialization planning often discover that processes built for clinical programs are difficult to adapt to commercial realities. By contrast, companies that begin preparing early have more opportunities to evaluate future-state requirements for operational gaps and build infrastructure capable of supporting growth. 

Commercial readiness, therefore, should be viewed as an ongoing strategic initiative rather than a late-stage launch activity. 

Visibility as a Competitive Advantage 

As supply chains become larger and more complex, visibility becomes increasingly critical. 

Gustafson points to real-time visibility as a foundational requirement for commercial operations. Stakeholders need access to timely, actionable information to identify emerging risks and make informed decisions. 

Visibility provides insight into how interconnected systems, partners, and processes are performing across the supply chain. When organizations can anticipate issues before they escalate, they are better positioned to meet regulatory expectations and protect patient access.  In an increasingly global and complex operating environment, proactive management is often only possible when supported by strong visibility and data-driven decision-making. 

The Strategic Value of Program Management 

Throughout her interview, Gustafson positioned program management as a critical enabler of commercial success. 

In commercialization, program management helps connect diverse stakeholders across manufacturing, quality, logistics, regulatory affairs, and commercial operations and provide the structure needed to manage dependencies and align priorities. 

As organizations scale, the role becomes even more important. Most often it’s not a single point of failure that challenges commercial entry.  More often, it is the cumulative effect of multiple small gaps across teams and processes that creates risk. Effective program management helps identify those gaps early and establish the frameworks necessary to address them. 

When implemented strategically, program management serves as the connector that enables organizations to grow without losing operational control. 

Maintaining a Patient-Centered Focus 

Although discussions about commercialization often center on logistics networks, operational infrastructure, and performance metrics, Gustafson ultimately ties these efforts back to patient impact.  

For advanced therapies, supply chain reliability is imperative for patient accessibility. Ensuring therapies reach patients safely and promptly requires a supply chain that can operate at scale without compromising quality. Every investment in visibility, process standardization, risk management, and program oversight contributes to that objective. 

Looking Ahead 

Gustafson’s perspective reinforces an important lesson for biopharmaceutical organizations navigating the path to commercialization: success depends on preparing for scale long before scale arrives. Companies that proactively build operational discipline, invest in visibility, and establish strong program management foundations are better equipped to manage growth and deliver consistent performance. 

The message is clear. We need to stop looking at commercial readiness as a milestone that begins just before launch, but rather as a continuous process of building the infrastructure, governance, and supply chain capabilities necessary to support patients as therapies move from clinical promise to commercial reality.